Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Generics Office Hopes To Begin Increasing Staff By Year-End

This article was originally published in The Pink Sheet Daily

Executive Summary

To aid in ANDA assignments, OGD is developing a program to prioritize submissions as the agency addresses a 3,000-application backlog, OGD Deputy Director Robert West says during regulatory affairs specialists’ gathering in Seattle.

You may also be interested in...

China SFDA Generics Report Acknowledges Industry And Regulator Have A Long Road Ahead

A rare government report criticizes practices of China’s generics industry and SFDA, officially highlighting well-recognized problems – from a lengthy registration process to a lack of pricing and bidding incentives – which need urgent attention.

Backlog Backfire: FDA Sees Increase In Pending Generic Applications At Deadline

The agency was expecting many pending generic drug submissions to be withdrawn because sponsors would not want to pay the one-time backlog fee, but instead saw a substantial increase near the end of FY 2012.

ANDA User Fee Negotiations Finished; Backlog To Be Mostly Cleared By Year Five

The finalized generic drug user fee agreement would clear most of the ANDA application backlog by the end of the first program cycle.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts